10 results on '"Van Acker, Heleen"'
Search Results
2. Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation
- Author
-
Capsomidis, Anna, Benthall, Gabriel, Van Acker, Heleen H., Fisher, Jonathan, Kramer, Anne M., Abeln, Zarah, Majani, Yvonne, Gileadi, Talia, Wallace, Rebecca, Gustafsson, Kenth, Flutter, Barry, and Anderson, John
- Abstract
Gamma delta T (γδT) lymphocytes are primed for rapid function, including cytotoxicity toward cancer cells, and are a component of the immediate stress response. Following activation, they can function as professional antigen-presenting cells. Chimeric antigen receptors (CARs) work by focusing T cell function on defined cell surface tumor antigens and provide essential costimulation for robust activation. Given the natural tropism of γδT cells for the tumor microenvironment, we hypothesized that their transduction with CARs might enhance cytotoxicity while retaining their ability to migrate to tumor and act as antigen-presenting cells to prolong the intratumoral immune response. Using a GD2-targeting CAR as a model system, we showed that γδT cells of both Vδ1 and Vδ2 subsets could be expanded and transduced to sufficient numbers for clinical studies. The CAR added to the cells’ innate cytotoxicity by enhancing GD2-specific killing of GD2-expressing cancer cell lines. Migration toward tumor cells in vitrowas not impaired by the presence of the CAR. Expanded CAR-transduced Vδ2 cells retained the ability to take up tumor antigens and cross presented the processed peptide to responder alpha beta T (αβT) lymphocytes. γδ CAR-T cell products show promise for evaluation in clinical studies of solid tumors.
- Published
- 2018
- Full Text
- View/download PDF
3. Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy
- Author
-
Anguille, Sébastien, Smits, Evelien L., Bryant, Christian, Van Acker, Heleen H., Goossens, Herman, Lion, Eva, Fromm, Phillip D., Hart, Derek N., Van Tendeloo, Viggo F., and Berneman, Zwi N.
- Abstract
Although the earliest—rudimentary—attempts at exploiting the immune system for cancer therapy can be traced back to the late 18th Century, it was not until the past decade that cancer immunotherapeutics have truly entered mainstream clinical practice. Given their potential to stimulate both adaptive and innate antitumor immune responses, dendritic cells (DCs) have come under intense scrutiny in recent years as pharmacological tools for cancer immunotherapy. Conceptually, the clinical effectiveness of this form of active immunotherapy relies on the completion of three critical steps: 1) the DCs used as immunotherapeutic vehicles must properly activate the antitumor immune effector cells of the host, 2) these immune effector cells must be receptive to stimulation by the DCs and be competent to mediate their antitumor effects, which 3) requires overcoming the various immune-inhibitory mechanisms used by the tumor cells. In this review, following a brief overview of the pivotal milestones in the history of cancer immunotherapy, we will introduce the reader to the basic immunobiological and pharmacological principles of active cancer immunotherapy using DCs. We will then discuss how current research is trying to define the optimal parameters for each of the above steps to realize the full clinical potential of DC therapeutics. Given its high suitability for immune interventions, acute myeloid leukemia was chosen here to showcase the latest research trends driving the field of DC-based cancer immunotherapy.
- Published
- 2015
- Full Text
- View/download PDF
4. Differential Roles of RND Efflux Pumps in Antimicrobial Drug Resistance of Sessile and Planktonic Burkholderia cenocepaciaCells
- Author
-
Buroni, Silvia, Matthijs, Nele, Spadaro, Francesca, Van Acker, Heleen, Scoffone, Viola C., Pasca, Maria Rosalia, Riccardi, Giovanna, and Coenye, Tom
- Abstract
ABSTRACTBurkholderia cenocepaciais notorious for causing respiratory tract infections in people with cystic fibrosis. Infections with this organism are particularly difficult to treat due to its high level of intrinsic resistance to most antibiotics. Multidrug resistance in B. cenocepaciacan be ascribed to different mechanisms, including the activity of efflux pumps and biofilm formation. In the present study, the effects of deletion of the 16 operons encoding resistance-nodulation-cell division (RND)-type efflux pumps in B. cenocepaciastrain J2315 were investigated by determining the MICs of various antibiotics and by investigating the antibiofilm effect of these antibiotics. Finally, the expression levels of selected RND genes in treated and untreated cultures were investigated using reverse transcriptase quantitative PCR (RT-qPCR). Our data indicate that the RND-3 and RND-4 efflux pumps are important for resistance to various antimicrobial drugs (including tobramycin and ciprofloxacin) in planktonic B. cenocepaciaJ2315 populations, while the RND-3, RND-8, and RND-9 efflux systems protect biofilm-grown cells against tobramycin. The RND-8 and RND-9 efflux pumps are not involved in ciprofloxacin resistance. Results from the RT-qPCR experiments on the wild-type strain B. cenocepaciaJ2315 suggest that there is little regulation at the level of mRNA expression for these efflux pumps under the conditions tested.
- Published
- 2014
- Full Text
- View/download PDF
5. Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy
- Author
-
Anguille, Sébastien, Lion, Eva, Van den Bergh, Johan, Van Acker, Heleen H, Willemen, Yannick, Smits, Evelien L, Van Tendeloo, Viggo F, and Berneman, Zwi N
- Abstract
Owing to their professional antigen-presenting capacity and unique potential to induce tumor antigen-specific T cell immunity, dendritic cells (DCs) have attracted much interest over the past decades for therapeutic vaccination against cancer. Clinical trials have shown that the use of tumor antigen-loaded DCs in cancer patients is safe and that it has the potential to induce anti-tumor immunity which, in some cases, culminates in striking clinical responses. Unfortunately, in a considerable number of patients, DC vaccination is unable to mount effective anti-tumor immune responses and, if it does so, the resultant immunity is often insufficient to translate into tangible clinical benefit. This underscores the necessity to re-design and optimize the current procedures for DC vaccine manufacturing. A new generation of DC vaccines with improved potency has now become available for clinical use as a result of extensive pre-clinical research. One of the promising next-generation DC vaccine candidates are interleukin (IL)-15-differentiated DCs. In this commentary, we will compile the research data that have been obtained by our group and other groups with these so-called IL-15 DCs and summarize the evidence supporting the implementation of IL-15 DCs in DC-based cancer vaccination regimens.
- Published
- 2013
- Full Text
- View/download PDF
6. Molecular Mechanisms of Chlorhexidine Tolerance in Burkholderia cenocepaciaBiofilms
- Author
-
Coenye, Tom, Van Acker, Heleen, Peeters, Elke, Sass, Andrea, Buroni, Silvia, Riccardi, Giovanna, and Mahenthiralingam, Eshwar
- Abstract
ABSTRACTThe high tolerance of biofilm-grown Burkholderia cepaciacomplex bacteria against antimicrobial agents presents considerable problems for the treatment of infected cystic fibrosis patients and the implementation of infection control guidelines. In the present study, we analyzed the tolerance of planktonic and sessile Burkholderia cenocepaciaJ2315 cultures and examined the transcriptional response of sessile cells to treatment with chlorhexidine. At low (0.0005%) and high (0.05%) concentrations, chlorhexidine had a similar effect on both populations, but at intermediate concentrations (0.015%) the antimicrobial activity was more pronounced in planktonic cultures. The exposure of sessile cells to chlorhexidine resulted in an upregulation of the transcription of 469 (6.56%) and the downregulation of 257 (3.59%) protein-coding genes. A major group of upregulated genes in the treated biofilms encoded membrane-related and regulatory proteins. In addition, several genes coding for drug resistance determinants also were upregulated. The phenotypic analysis of RND (resistance-nodulation-division) efflux pump mutants suggests the presence of lifestyle-specific chlorhexidine tolerance mechanisms; efflux system RND-4 (BCAL2820-BCAL2822) was more responsible for chlorhexidine tolerance in planktonic cells, while other systems (RND-3 [BCAL1672-BCAL1676] and RND-9 [BCAM1945-BCAM1947]) were linked to resistance in sessile cells. After sessile cell exposure, multiple genes encoding chemotaxis and motility-related proteins were upregulated in concert with the downregulation of an adhesin-encoding gene (BCAM2143), suggesting that sessile cells tried to escape the biofilm. We also observed the differential expression of 19 genes carying putative small RNA molecules, indicating a novel role for these regulatory elements in chlorhexidine tolerance.
- Published
- 2011
- Full Text
- View/download PDF
7. Various Evolutionary Trajectories Lead to Loss of the Tobramycin-Potentiating Activity of the Quorum-Sensing Inhibitor Baicalin Hydrate in Burkholderia cenocepaciaBiofilms
- Author
-
Sass, Andrea, Slachmuylders, Lisa, Van Acker, Heleen, Vandenbussche, Ian, Ostyn, Lisa, Bové, Mona, Crabbé, Aurélie, Chiarelli, Laurent R., Buroni, Silvia, Van Nieuwerburgh, Filip, Abatih, Emmanuel, and Coenye, Tom
- Abstract
Combining antibiotics with potentiators that increase their activity is a promising strategy to tackle infections caused by antibiotic-resistant bacteria. As potentiators do not interfere with essential processes, it has been hypothesized that they are less likely to induce resistance.
- Published
- 2019
- Full Text
- View/download PDF
8. Targeting the Nonmevalonate Pathway in Burkholderia cenocepaciaIncreases Susceptibility to Certain β-Lactam Antibiotics
- Author
-
Sass, Andrea, Everaert, Annelien, Van Acker, Heleen, Van den Driessche, Freija, and Coenye, Tom
- Abstract
ABSTRACTThe nonmevalonate pathway is the sole pathway for isoprenoid biosynthesis in Burkholderia cenocepaciaand is possibly a novel target for the development of antibacterial chemotherapy. The goals of the present study were to evaluate the essentiality of dxr, the second gene of the nonmevalonate pathway, in B. cenocepaciaand to determine whether interfering with the nonmevalonate pathway increases susceptibility toward antibiotics. To this end, a rhamnose-inducible conditional dxrknockdown mutant of B. cenocepaciastrain K56-2 (B. cenocepaciaK56-2dxr) was constructed, using a plasmid which enables the delivery of a rhamnose-inducible promoter in the chromosome. Expression of dxris essential for bacterial growth; the growth defect observed in the dxrmutant could be complemented by expressing dxr in transunder the control of a constitutive promoter, but not by providing 2-C-methyl-d-erythritol-4-phosphate, the reaction product of DXR (1-deoxy-d-xylulose 5-phosphate reductoisomerase). B. cenocepaciaK56-2dxrshowed markedly increased susceptibility to the β-lactam antibiotics aztreonam, ceftazidime, and cefotaxime, while susceptibility to other antibiotics was not (or was much less) affected; this increased susceptibility could also be complemented by in transexpression of dxr. A similarly increased susceptibility was observed when antibiotics were combined with FR900098, a known DXR inhibitor. Our data confirm that the nonmevalonate pathway is essential in B. cenocepaciaand suggest that combining potent DXR inhibitors with selected β-lactam antibiotics is a useful strategy to combat B. cenocepaciainfections.
- Published
- 2018
- Full Text
- View/download PDF
9. Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in inducing NK cell cytotoxicity
- Author
-
van Beek, Jasper J. P., Gorris, Mark A. J., Sköld, Annette E., Hatipoglu, Ibrahim, Van Acker, Heleen H., Smits, Evelien L., de Vries, I. Jolanda M., and Bakdash, Ghaith
- Abstract
ABSTRACTHuman blood dendritic cells (DCs) hold great potential for use in anticancer immunotherapies. CD1c+myeloid DCs and plasmacytoid DCs (pDCs) have been successfully utilized in clinical vaccination trials against melanoma. We hypothesize that combining both DC subsets in a single vaccine can further improve vaccine efficacy. Here, we have determined the potential synergy between the two subsets in vitroon the level of maturation, cytokine expression, and effector cell induction. Toll-like receptor (TLR) stimulation of CD1c+DCs induced cross-activation of immature pDCs and vice versa. When both subsets were stimulated together using TLR agonists, CD86 expression on pDCs was increased and higher levels of interferon (IFN)-α were produced by DC co-cultures. Although the two subsets did not display any synergistic effect on naive CD4+and CD8+T cell polarization, CD1c+DCs and pDCs were able to complement each other's induction of other immune effector cells. The mere presence of pDCs in DC co-cultures promoted plasma cell differentiation from activated autologous B cells. Similarly, CD1c+DCs, alone or in co-cultures, induced high levels of IFN-γ from allogeneic peripheral blood lymphocytes or activated autologous natural killer (NK) cells. Both CD1c+DCs and pDCs could enhance NK cell cytotoxicity, and interestingly DC co-cultures further enhanced NK cell-mediated killing of an NK-resistant tumor cell line. These results indicate that co-application of human blood DC subsets could render DC-based anticancer vaccines more efficacious.
- Published
- 2016
- Full Text
- View/download PDF
10. Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy
- Author
-
Van Acker, Heleen H, Anguille, Sébastien, Van Tendeloo, Viggo F, and Lion, Eva
- Abstract
Gamma delta (γδ) T cells are the all-rounders of our immune-system with their major histocompatibility complex-unrestricted cytotoxicity, capacity to secrete immunosti-mulatory cytokines and ability to promote the generation of tumor antigen-specific CD8+and CD4+T cell responses. Dendritic cell (DC)-based vaccine therapy has the prospective to harness these unique features of the γδ T cells in the fight against cancer. In this review, we will discuss our current knowledge on DC-mediated γδ T cell activation and related opportunities for tumor immunologists.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.